Literature DB >> 10763094

Other smoking-affected pulmonary diseases.

S Murin1, K S Bilello, R Matthay.   

Abstract

Cigarette smoking is the leading cause of preventable death in the United States. Smoking adversely affects many organ systems, but especially the lung. Carcinoma of the lung and chronic obstructive pulmonary disease account for most smoking-associated respiratory morbidity and mortality, and their association with smoking is both well established and widely recognized. Cigarette smoking also is associated with differences in the incidence, severity, or natural history of a broad array of other respiratory illnesses, ranging from the common cold to pneumothorax, pulmonary hemorrhage, and various interstitial lung diseases. Interestingly, while the general effect of smoking on respiratory diseases is adverse, in the cases of sarcoidosis and hypersensitivity pneumonitis smoking may actually be associated with a decrease in the incidence of disease. In this article, the author briefly discusses some of the pulmonary and systemic effects of smoking that might mediate its effects on an array of lung diseases, then comprehensively reviews less common or less well-recognized smoking-affected lung diseases such as pulmonary infections, spontaneous pneumothorax, Goodpasture's syndrome, eosinophilic granuloma and other interstitial lung diseases, and pulmonary metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10763094     DOI: 10.1016/s0272-5231(05)70012-5

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  13 in total

1.  High-dose but not low-dose mainstream cigarette smoke suppresses allergic airway inflammation by inhibiting T cell function.

Authors:  Thomas H Thatcher; Randi P Benson; Richard P Phipps; Patricia J Sime
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-06-20       Impact factor: 5.464

2.  Disparities in smoking and acute respiratory illnesses among sexual minority young adults.

Authors:  John Blosnich; Traci Jarrett; Kimberly Horn
Journal:  Lung       Date:  2010-05-23       Impact factor: 2.584

3.  Cigarette smoke and bleomycin-induced pulmonary oxidative stress in rats.

Authors:  Turgut Teke; Emin Maden; Aysel Kiyici; Celalettin Korkmaz; Mehmet Gok; Faruk Ozer; Oktay Imecik; Kursat Uzun1
Journal:  Exp Ther Med       Date:  2012-04-17       Impact factor: 2.447

4.  The clinical and radiologic features of nodular pulmonary sarcoidosis.

Authors:  Subramanian Malaisamy; Bhavinkumar Dalal; Christian Bimenyuy; Ayman O Soubani
Journal:  Lung       Date:  2008-10-09       Impact factor: 2.584

5.  Self-rated Health and Medical Conditions in Refugees and Immigrants from the Same Country of Origin.

Authors:  Hikmet Jamil; Evone Barkho; Carissa L Broadbridge; Matthew Ventimiglia; Judith E Arnetz; Faris Lami; Bengt B Arnetz
Journal:  Iraqi J Med Sci       Date:  2015

6.  Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate.

Authors:  Gong Yong Jin; David Lynch; Ashish Chawla; Kavita Garg; Martin C Tammemagi; Hakan Sahin; Shigeki Misumi; Keun Sang Kwon
Journal:  Radiology       Date:  2013-03-19       Impact factor: 11.105

Review 7.  Epidemiology of sarcoidosis: current findings and future directions.

Authors:  Elizabeth V Arkema; Yvette C Cozier
Journal:  Ther Adv Chronic Dis       Date:  2018-08-24       Impact factor: 5.091

8.  Lung injury after cigarette smoking is particle related.

Authors:  Rahul G Sangani; Andrew J Ghio
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-03-10

9.  Human pathogens abundant in the bacterial metagenome of cigarettes.

Authors:  Amy R Sapkota; Sibel Berger; Timothy M Vogel
Journal:  Environ Health Perspect       Date:  2009-10-22       Impact factor: 9.031

10.  Rhesus factor modulation of effects of smoking and age on psychomotor performance, intelligence, personality profile, and health in Czech soldiers.

Authors:  Jaroslav Flegr; Jan Geryk; Jindra Volný; Jiří Klose; Dana Cernochová
Journal:  PLoS One       Date:  2012-11-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.